Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Combination Chemotherapy With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

20 giugno 2013 aggiornato da: Southwest Oncology Group

Randomized Phase III Trial Of Carboplatin And Paclitaxel Plus Tirapazamine Versus Carboplatin And Paclitaxel In Patients With Advanced Non-Small Cell Lung Cancer

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which combination chemotherapy regimen is more effective for non-small cell lung cancer.

PURPOSE: Randomized phase III trial to compare the effectiveness of carboplatin plus paclitaxel with or without tirapazamine in treating patients who have stage IIIB or stage IV non-small cell lung cancer.

Panoramica dello studio

Stato

Completato

Condizioni

Intervento / Trattamento

Descrizione dettagliata

OBJECTIVES:

  • Compare the effects of paclitaxel and carboplatin with or without tirapazamine on progression-free survival and overall survival in patients with stage IV and selected stage IIIB non-small cell lung cancer.
  • Compare response rates in patients treated with these regimens.
  • Compare the toxic effects of these regimens in these patients.

OUTLINE: This is a randomized study. Patients are stratified according to weight loss (less than 5% vs 5% or more), stage of disease (IIIB vs IV), and lactate dehydrogenase level (normal vs abnormal). Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive tirapazamine IV over 2 hours followed by paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1.
  • Arm II: Patients receive paclitaxel and carboplatin as in arm I. Treatment continues every 21 days for a total of 6 courses in the absence of disease progression or unacceptable toxicity.

Patients are followed every 3 months for one year, and then every 6 months for 2 years, or until death.

PROJECTED ACCRUAL: Approximately 500 patients (250 per arm) will be accrued for this study within 20 months.

Tipo di studio

Interventistico

Fase

  • Fase 3

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

  • Stati Uniti
    • Alabama
      • Mobile, Alabama, Stati Uniti, 36688
        • MBCCOP - Gulf Coast
    • Arizona
      • Phoenix, Arizona, Stati Uniti, 85006-2726
        • CCOP - Greater Phoenix
      • Phoenix, Arizona, Stati Uniti, 85012
        • Veterans Affairs Medical Center - Phoenix (Hayden)
      • Tucson, Arizona, Stati Uniti, 85724
        • Arizona Cancer Center
      • Tucson, Arizona, Stati Uniti, 85723
        • Veterans Affairs Medical Center - Tucson
    • Arkansas
      • Little Rock, Arkansas, Stati Uniti, 72205
        • University of Arkansas for Medical Sciences
      • Little Rock, Arkansas, Stati Uniti, 72205
        • Veterans Affairs Medical Center - Little Rock (McClellan)
    • California
      • Duarte, California, Stati Uniti, 91010-3000
        • Cancer Center and Beckman Research Institute, City of Hope
      • Los Angeles, California, Stati Uniti, 90095-1781
        • Jonsson Comprehensive Cancer Center, UCLA
      • Los Angeles, California, Stati Uniti, 90033-0804
        • USC/Norris Comprehensive Cancer Center and Hospital
      • Martinez, California, Stati Uniti, 94553
        • Veterans Affairs Outpatient Clinic - Martinez
      • Oakland, California, Stati Uniti, 94609-3305
        • CCOP - Bay Area Tumor Institute
      • Orange, California, Stati Uniti, 92868
        • Chao Family Comprehensive Cancer Center
      • Sacramento, California, Stati Uniti, 95817
        • University of California Davis Cancer Center
      • San Francisco, California, Stati Uniti, 94143-0128
        • UCSF Cancer Center and Cancer Research Institute
      • Santa Rosa, California, Stati Uniti, 95403
        • CCOP - Santa Rosa Memorial Hospital
      • Travis Air Force Base, California, Stati Uniti, 94535
        • David Grant Medical Center
    • Colorado
      • Denver, Colorado, Stati Uniti, 80220
        • Veterans Affairs Medical Center - Denver
      • Denver, Colorado, Stati Uniti, 80010
        • University of Colorado Cancer Center
    • Georgia
      • Atlanta, Georgia, Stati Uniti, 30342-1701
        • CCOP - Atlanta Regional
      • Fort Gordon, Georgia, Stati Uniti, 30905-5650
        • Dwight David Eisenhower Army Medical Center
    • Hawaii
      • Honolulu, Hawaii, Stati Uniti, 96813
        • Cancer Research Center of Hawaii
    • Illinois
      • Chicago, Illinois, Stati Uniti, 60612-7323
        • MBCCOP - University of Illinois at Chicago
      • Chicago, Illinois, Stati Uniti, 60612
        • Veterans Affairs Medical Center - Chicago (Westside Hospital)
      • Decatur, Illinois, Stati Uniti, 62526
        • CCOP - Central Illinois
      • Hines, Illinois, Stati Uniti, 60141
        • Veterans Affairs Medical Center - Hines (Hines Junior VA Hospital)
      • Maywood, Illinois, Stati Uniti, 60153
        • Loyola University Medical Center
    • Iowa
      • Bettendorf, Iowa, Stati Uniti, 52722
        • Hematology Oncology Associates of the Quad Cities
    • Kansas
      • Kansas City, Kansas, Stati Uniti, 66160-7357
        • University of Kansas Medical Center
      • Wichita, Kansas, Stati Uniti, 67214-3882
        • CCOP - Wichita
      • Wichita, Kansas, Stati Uniti, 67218
        • Veterans Affairs Medical Center - Wichita
    • Kentucky
      • Lexington, Kentucky, Stati Uniti, 40511-1093
        • Veterans Affairs Medical Center - Lexington
      • Lexington, Kentucky, Stati Uniti, 40536-0084
        • Albert B. Chandler Medical Center, University of Kentucky
    • Louisiana
      • New Orleans, Louisiana, Stati Uniti, 70112
        • Tulane University School of Medicine
      • New Orleans, Louisiana, Stati Uniti, 70112
        • MBCCOP - LSU Health Sciences Center
      • Shreveport, Louisiana, Stati Uniti, 71130-3932
        • Louisiana State University Health Sciences Center - Shreveport
      • Shreveport, Louisiana, Stati Uniti, 71130
        • Veterans Affairs Medical Center - Shreveport
    • Massachusetts
      • Boston, Massachusetts, Stati Uniti, 02118
        • Boston Medical Center
      • Jamaica Plain, Massachusetts, Stati Uniti, 02130
        • Veterans Affairs Medical Center - Boston (Jamaica Plain)
    • Michigan
      • Ann Arbor, Michigan, Stati Uniti, 48109-0752
        • University of Michigan Comprehensive Cancer Center
      • Ann Arbor, Michigan, Stati Uniti, 48105
        • Veterans Affairs Medical Center - Ann Arbor
      • Ann Arbor, Michigan, Stati Uniti, 48106
        • CCOP - Ann Arbor Regional
      • Detroit, Michigan, Stati Uniti, 48202
        • Henry Ford Hospital
      • Detroit, Michigan, Stati Uniti, 48201-1379
        • Barbara Ann Karmanos Cancer Institute
      • Detroit, Michigan, Stati Uniti, 48201-1932
        • Veterans Affairs Medical Center - Detroit
      • Southfield, Michigan, Stati Uniti, 48075-9975
        • Providence Hospital - Southfield
    • Minnesota
      • Duluth, Minnesota, Stati Uniti, 55805
        • CCOP - Duluth
    • Mississippi
      • Biloxi, Mississippi, Stati Uniti, 39531-2410
        • Veterans Affairs Medical Center - Biloxi
      • Jackson, Mississippi, Stati Uniti, 39216-4505
        • University of Mississippi Medical Center
      • Jackson, Mississippi, Stati Uniti, 39216
        • Veterans Affairs Medical Center - Jackson
      • Keesler AFB, Mississippi, Stati Uniti, 39534-2576
        • Keesler Medical Center - Keesler AFB
    • Missouri
      • Kansas City, Missouri, Stati Uniti, 64128
        • Veterans Affairs Medical Center - Kansas City
      • Kansas City, Missouri, Stati Uniti, 64131
        • CCOP - Kansas City
      • Saint Louis, Missouri, Stati Uniti, 63110-0250
        • St. Louis University Health Sciences Center
      • Saint Louis, Missouri, Stati Uniti, 63141
        • CCOP - St. Louis-Cape Girardeau
      • Springfield, Missouri, Stati Uniti, 65807
        • CCOP - Cancer Research for the Ozarks
    • Montana
      • Billings, Montana, Stati Uniti, 59101
        • CCOP - Montana Cancer Consortium
    • New Mexico
      • Albuquerque, New Mexico, Stati Uniti, 87108-5138
        • Veterans Affairs Medical Center - Albuquerque
      • Albuquerque, New Mexico, Stati Uniti, 87131
        • MBCCOP - University of New Mexico HSC
    • New York
      • Albany, New York, Stati Uniti, 12208
        • Veterans Affairs Medical Center - Albany
      • New York, New York, Stati Uniti, 10032
        • Herbert Irving Comprehensive Cancer Center
      • Rochester, New York, Stati Uniti, 14642
        • University of Rochester Medical Center
    • North Carolina
      • Winston-Salem, North Carolina, Stati Uniti, 27104-4241
        • CCOP - Southeast Cancer Control Consortium
    • Ohio
      • Cincinnati, Ohio, Stati Uniti, 45220-2288
        • Veterans Affairs Medical Center - Cincinnati
      • Cincinnati, Ohio, Stati Uniti, 45267-0502
        • Barrett Cancer Center, The University Hospital
      • Cleveland, Ohio, Stati Uniti, 44195
        • Cleveland Clinic Taussig Cancer Center
      • Columbus, Ohio, Stati Uniti, 43206
        • CCOP - Columbus
      • Dayton, Ohio, Stati Uniti, 45428
        • Veterans Affairs Medical Center - Dayton
      • Kettering, Ohio, Stati Uniti, 45429
        • CCOP - Dayton
      • Toledo, Ohio, Stati Uniti, 43623-3456
        • CCOP - Toledo Community Hospital Oncology Program
    • Oklahoma
      • Oklahoma City, Oklahoma, Stati Uniti, 73104
        • Oklahoma Medical Research Foundation
      • Oklahoma City, Oklahoma, Stati Uniti, 73104
        • Veterans Affairs Medical Center - Oklahoma City
    • Oregon
      • Portland, Oregon, Stati Uniti, 97207
        • Veterans Affairs Medical Center - Portland
      • Portland, Oregon, Stati Uniti, 97213
        • CCOP - Columbia River Program
      • Portland, Oregon, Stati Uniti, 97201-3098
        • Oregon Cancer Center
    • South Carolina
      • Charleston, South Carolina, Stati Uniti, 29425-0721
        • Medical University of South Carolina
      • Charleston, South Carolina, Stati Uniti, 29401-5799
        • Veterans Affairs Medical Center - Charleston
      • Greenville, South Carolina, Stati Uniti, 29615
        • CCOP - Greenville
      • Spartanburg, South Carolina, Stati Uniti, 29303
        • CCOP - Upstate Carolina
    • Texas
      • Fort Sam Houston, Texas, Stati Uniti, 78234
        • Brooke Army Medical Center
      • Galveston, Texas, Stati Uniti, 77555-0209
        • University of Texas Medical Branch
      • Houston, Texas, Stati Uniti, 77030
        • Veterans Affairs Medical Center - Houston
      • San Antonio, Texas, Stati Uniti, 78284-7811
        • University of Texas Health Science Center at San Antonio
      • San Antonio, Texas, Stati Uniti, 78284
        • Veterans Affairs Medical Center - San Antonio (Murphy)
      • Temple, Texas, Stati Uniti, 76504
        • Veterans Affairs Medical Center - Temple
      • Temple, Texas, Stati Uniti, 76508
        • CCOP - Scott and White Hospital
    • Utah
      • Salt Lake City, Utah, Stati Uniti, 84148
        • Veterans Affairs Medical Center - Salt Lake City
      • Salt Lake City, Utah, Stati Uniti, 84112
        • Huntsman Cancer Institute
    • Washington
      • Seattle, Washington, Stati Uniti, 98101
        • CCOP - Virginia Mason Research Center
      • Seattle, Washington, Stati Uniti, 98104
        • Swedish Cancer Institute
      • Seattle, Washington, Stati Uniti, 98108
        • Veterans Affairs Medical Center - Seattle
      • Tacoma, Washington, Stati Uniti, 98431-5000
        • Madigan Army Medical Center
      • Tacoma, Washington, Stati Uniti, 98405-0986
        • CCOP - Northwest

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

DISEASE CHARACTERISTICS:

  • Histologically or cytologically proven newly diagnosed advanced primary non-small cell lung cancer (NSCLC), including the following cellular types:

    • Adenocarcinoma
    • Large cell carcinoma
    • Squamous cell carcinoma
    • Unspecified carcinoma OR
  • Recurrent disease after prior surgery and/or radiotherapy

  • Stage IIIB disease

    • T4 lesion due to malignant pleural effusion OR

  • Stage IV disease

    • Any T, any N, M1 (distant metastasis, including lesions in multiple lobes of the ipsilateral lung)

  • Measurable or evaluable disease

    • Pleural effusions, ascites, and laboratory parameters not considered as only evidence of disease
    • Must be outside prior radiated field or area of prior surgical resection or new lesion must be present
  • No known brain metastases

PATIENT CHARACTERISTICS:

Age:

  • 18 and over

Performance status:

  • Zubrod 0-1

Life expectancy:

  • Not specified

Hematopoietic:

  • Absolute granulocyte count at least 1,500/mm^3
  • Platelet count at least 100,000/mm^3
  • Hemoglobin at least 9 g/dL

Hepatic:

  • Bilirubin no greater than 2 times upper limit of normal (ULN)
  • SGOT or SGPT no greater than 2 times ULN
  • Alkaline phosphatase no greater than 2 times ULN

Renal:

  • Creatinine no greater than ULN
  • Creatinine clearance at least 50 mL/min

Other:

  • Not pregnant or nursing
  • Fertile patients must use effective contraception
  • No peripheral neuropathy (motor or sensory) of grade 2 or greater
  • No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or stage I/II cancer in complete remission

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • No prior biologic therapy for NSCLC

Chemotherapy:

  • No prior systemic chemotherapy for NSCLC

Endocrine therapy:

  • Not specified

Radiotherapy:

  • See Disease Characteristics
  • At least 3 weeks since prior radiotherapy and recovered
  • No concurrent radiotherapy

Surgery:

  • See Disease Characteristics
  • At least 2 weeks since prior thoracic or other major surgery and recovered

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Southwest Oncology Group

Collaboratori

National Cancer Institute (NCI)

Investigatori

  • Cattedra di studio: Stephen K. Williamson, MD, University of Kansas

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio

1 novembre 2000

Completamento dello studio (Effettivo)

1 aprile 2006

Date di iscrizione allo studio

Primo inviato

6 novembre 2000

Primo inviato che soddisfa i criteri di controllo qualità

30 maggio 2003

Primo Inserito (Stima)

2 giugno 2003

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Stima)

24 giugno 2013

Ultimo aggiornamento inviato che soddisfa i criteri QC

20 giugno 2013

Ultimo verificato

1 gennaio 2002

Maggiori informazioni

Termini relativi a questo studio

Parole chiave

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • CDR0000068315
  • SWOG-S0003

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su Cancro ai polmoni

Prove cliniche su carboplatino

Cerca prove simili

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

CROs by country

CROs in Egypt

Condizioni

Malattie rare

Interventi farmacologici

Supplementi dietetici

Sponsor / Collaboratori

Sedi

3
Sottoscrivi